12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Sun, 13 Jul 2025 03:33:54 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Server: cloudflare [5] => Nel: {"report_to":"cf-nel","success_fraction":0.0,"max_age":604800} [6] => Vary: Accept-Encoding [7] => X-Powered-By: PHP/7.4.33 [8] => Cache-Control: no-cache, private [9] => X-Frame-Options: SAMEORIGIN [10] => X-Xss-Protection: 1; mode=block [11] => X-Content-Type-Options: nosniff [12] => Referrer-Policy: no-referrer-when-downgrade [13] => Report-To: {"group":"cf-nel","max_age":604800,"endpoints":[{"url":"https://a.nel.cloudflare.com/report/v4?s=OYiFFrIsHKu9aTPZaID2DNjcR6m4eJjEHGDfqE6Etslzt1n8xiXKM0D5KroFTOovvuS%2BtoheVrLPGiZQAlJS%2Bm3%2FQnShl2M2sbARYEE%3D"}]} [14] => Cf-Cache-Status: DYNAMIC [15] => Server-Timing: cfCacheStatus;desc="DYNAMIC" [16] => Server-Timing: cfEdge;dur=3,cfOrigin;dur=2 [17] => Set-Cookie: UpalLiveSession=eyJpdiI6IldjS1BWSVN1SE91aXlqUDVBSmZrYmc9PSIsInZhbHVlIjoiZ3lxXC9yQjZ5akQrMUZQbFZ5R3FERGpCYUxoeSs5MHVGd20rVzI0RGdjR2wrTlRsdEZcLzBkYXdIMTdaaEVMXC9kc01lOStpQWNPRTZxZjI0ZFZHN3VNOEE9PSIsIm1hYyI6IjhiNDlhNjc4Y2EzMTdkZDZlMzU4ZDNlYjZhNGE1ODEwNTgyMmFmNzJjODhmNjQ5MDIyMzcyNzRkYjM3OWU3MDAifQ%3D%3D; HttpOnly; Path=/; Max-Age=94608000; Expires=Wed, 12 Jul 2028 02:44:59 GMT [18] => CF-RAY: 95e5b8b56dffd432-KUL [19] => alt-svc: h3=":443"; ma=86400 ) 789

美国吉利德科学公司研发的药物“瑞德西韦”，被认为可望抑制新型冠状病毒感染，中国科学家于周三已在武汉启动临床试验，用于治疗新冠肺炎患者。

媒体报导，主导瑞德西韦研发工作的是来自台湾的女科学家，也就是吉利德制药部门执行副总裁杨台莹。

根据吉利德网站介绍，杨台莹毕业于台湾大学化学系，也拥有南加州大学有机化学博士学位。

她领导吉利德的药物研发与制造部门，负责该公司研发与上市产品。在她的领导下，吉利德研发出全球第一款治疗HIV单锭药物，也将多于25种复方制剂研发成药品。

北京“中日友好医院”的王辰、曹彬团队于周三下午在武汉市金银潭医院宣布启动瑞德西韦治疗2019新型冠状病毒感染临床3期研究，首批试验761位患者。

---

// // // //